GLPwatch
Tirzepatide for weight reduction in people without diabetes.
Drug Ther Bull · 2025
Last updated 2026-05-28In a study of 2,539 adults without diabetes, tirzepatide taken once weekly led to weight reductions of 15% to 20.9% over 72 weeks, depending on the dose (5 mg, 10 mg, or 15 mg). The highest dose (15 mg) resulted in an average weight loss of 20.9% compared to 3.1% with placebo.
AI summary of the abstract below.
| Journal | Drug Ther Bull, 2025 |
|---|---|
| Citations | 0 |
| Molecules | tirzepatide |
| Conditions studied | Obesity |
Abstract
Jastreboff AM, Aronne LJ, Ahmad NN, Tirzepatide Once Weekly for the Treatment of Obesity. 2022;387:205-216.
Verbatim abstract via PubMed 40461177 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.